A Possible Guide as a Tool to Complementary Effects of New Coronavirus
-
Afsaneh Sadremomtaz
,
Javad Hashemi
,
Adeleh Sahebnasagh
,
Seyed Mohammad Nabavi
,
Zayana M.Al-Dahmani
,
Shayesteh Gheibi
,
Bita Shahrami
,
Reza Mosaed
,
Peyman Arfa
,
Soheil Roshanzamiri
,
Mojtaba Mojtahedzadeh
Abstract
At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by the upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage. Ultimately the minority of patients progress to stage III with high mortality.
The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak.
At the end of 2019, Sars-CoV-2 was identified and has since spread in the world. Coronavirus is commonly caused by the upper respiratory tract and severe acute respiratory syndrome in humans. Due to the novel nature of the virus and high mortality among high-risk people, today health care providers used several medications with different mechanisms to overcome this virus. The course of COVID-19 represents three stages that have different symptoms and used different drugs depends on each stage. Ultimately the minority of patients progress to stage III with high mortality.
The aim of this study is a comprehensive review of COVID-19 adjuvant therapies. We explained the current study on the use of Glucocorticoids, Interferon, Vitamin C, Tocilizumab, Anakinra, Pentoxifylline, IVIG, Allopurinol, Ivermectin, and Selenium in sepsis, pneumonia, and ARDS and we suggested a new protocol for prescribing each medication currently used in COVID-19 Outbreak.
[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-33.
[2] Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020; 886:173451.
[3] Aguilar RB, Hardigan P, Mayi B, Sider D, Piotrkowski J, Mehta JP, et al. Current Understanding of COVID-19 Clinical Course and Investigational Treatments. Front Med (Lausanne). 2020; 7:555301.
[4] Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020; 2(10):e594-e602.
[5] Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-81.
[6] Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-47.
[7] Li Y, Wang S, Gao H, Wang J, Wei C, Chen L, et al. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence. Zhonghua Yi Xue Za Zhi. 2004; 84(16):1348.
[8] Azimi S, Sahebnasagh A, Sharifnia H, Najmeddin F. Corticosteroids Administration Following COVID-19-induced Acute Respiratory Distress Syndrome. Is it harmful or Life-saving? Front Emerg Med. 2020;4(2s):e43.
[9] Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005; 353(16):1711-23.
[10] Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-67.
[11] Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9.
[12] Yam LY-C, Lau AC-W, Lai FY-L, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007; 54(1):28-39.
[13] Chen R-c, Tang X-p, Tan S-y, Liang B-l, Wan Z-y, Fang J-q, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6):1441-52.
[14] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473-5.
[15] Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet (London, England). 2020; 395(10225):683.
[16] Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020; 5(1):1-3.
[17] Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-43.
[18] Ni Y-N, Liu Y-M, Wang Y-W, Liang B-M, Liang Z-A. Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis. Am J Emerg Med. 2019; 37(9):1657-64.
[19] Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):e98-e106.
[20] Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care. 2019; 23(1):99.
[21] Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015; 10(12):e0144032.
[22] Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between Administration of Systemic Corticosteroids and Mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324(13):1330-41.
[23] Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021; 72(9):e373-e381.
[24] The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial. Chinese Clinical Trial Register (Internet) IC IC, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=50453
[25] Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure. Available from: ClinicalTrials.gov identifier (NCT number): NCT04244591 AFhcgcsNtNcC-dr.
[26] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000029656, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49086
[27] Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv. 2020.
[28] Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020; 52(1):1-5.
[29] Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014; 14(11):1090-5.
[30] Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020; 72(6):1446-1478.
[31] Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020; 25(4):668-88.
[32] Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl Jr J. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005; 326(4):905-8.
[33] Wang L-s, Wang Y-r, Ye D-w, Liu Q-q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020; 56(3): 106137.
[34] Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng C-TK, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008; 82(9):4471-9.
[35] Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006;103(34):12885-90.
[36] Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health. 2018; 11(1):9-17.
[37] Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020; 9(3):623.
[38] Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
[39] Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88:106903.
[40] Jianping Z, Huilan Z. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients. ClinicalTrials.gov identifier (NCT number): NCT04293887 AFhcgcsN.
[41] Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-704.
[42] Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9).
[43] Li C, Luo F, Liu C, Xiong N, Xu Z, Zhang W, et al. Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients. Research Square. 2020.
[44] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000029989, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49720
[45] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000030013, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49796
[46] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000030480, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=50470
[47] Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020; 85:106688.
[48] Payandemehr P, Azhdarzadeh M, Bahrami-Motlagh H, Hadadi A, Najmeddin F, Shahmirzaei S, et al. Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-Label Single-Arm Clinical Trial. Front Emerg Med. 2020;4(2s):e51.
[49] A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. ClinicalTrials.gov identifier (NCT number): NCT04254874.
[50] Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J-M, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 1996;24(3):392-7.
[51] Nakano K, Suzuki S. Stress-induced change in tissue levels of ascorbic acid and histamine in rats. J Nutr. 1984; 114(9):1602-8.
[52] Kuhn S-O, Meissner K, Mayes LM, Bartels K. Vitamin C in sepsis. Curr Opin Anaesthesiol. 2018; 31(1):55.
[53] Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020; 100190.
[54] Chang P, Liao Y, Guan J, Guo Y, Zhao M, Hu J, et al. Combined treatment with hydrocortisone, vitamin C, and thiamine for sepsis and septic shock (HYVCTTSSS): A randomized controlled clinical trial. Chest. 2020; 158(1):174-182.
[55] Iglesias J, Vassallo AV, Patel VV, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis. Chest. 2020; 158(1):164-173.
[56] Baladia E, Pizarro AB, Ortiz-Muñoz L, Rada G, Group C-LOW. Vitamin C for COVID-19: A living systematic review. Medwave. 2020; 20(6).
[57] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020; 92(7):814-8.
[58] Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):1-5.
[59] Gheibi S, Najmeddin F, Shahrami B, Sadeghi K, Mojtahedzadeh M. The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19. J Pharm Care. 2020;8(3):140-2.
[60] Ibrahim YF, Moussa RA, Bayoumi AM, Ahmed A-SF. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein. Inflammopharmacology. 2020; 28(1):215-30.
[61] Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018; 23(8):943.
[62] Radigan KA, Nicholson TT, Welch LC, Chi M, Amarelle L, Angulo M, et al. Influenza A virus infection induces muscle wasting via IL-6 regulation of the E3 ubiquitin ligase atrogin-1. The Journal of Immunology. 2019; 202(2):484-93.
[63] Masui-Ito A, Okamoto R, Ikejiri K, Fujimoto M, Tanimura M, Nakamori S, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: Case report and review of literature. Medicine. 2017; 96(29).
[64] Roche H-L. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA). 2020; ClinicalTrials.gov Identifier: NCT04320615
[65] Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20(5):269-70.
[66] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-5.
[67] Tongji Hospital HXH, Hospital WN, hospital Wc. Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS) clinicaltrials.gov Identifier: NCT043067052020
[68] Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis (Internet). 2020; ClinicalTrials.gov Identifier: NCT04315480.
[69] Giamarellos-Bourboulis EJ. Supar-Guided Anakinra Treatment For Validation Of The Risk And Early Management Of Severe Respiratory Failure By Covid-19. 2020; ClinicalTrials.gov Identifier: NCT04357366
[70] Giamarellos-Bourboulis EJ, Netea MG. A Personalized Randomized Trial Of Validation And Restoration Of Immune Dysfunction In Severe Infections And Sepsis (The Provide Trial). 2017; ClinicalTrials.gov Identifier: NCT03332225
[71] Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014; 15(5):401-8.
[72] Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial. Crit Care Med. 2016; 44(2):275-81.
[73] Nowill AE, de Campos-Lima PO. Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2–Induced Cytokine Storm. J Immunol. 2020; 205(10):2566-2575.
[74] Mer CHIdTLSs. Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV) (JAKINKOV) ClinicalTrials.gov Identifier: NCT043662322020
[75] Pedro Abizanda CHUdA. Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults (COVID-AGE). 2020; Available from: NCT04362943.
[76] Biovitrum SO. Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients with COVID-19 Infection. 2020; Available from: NCT04324021
[77] Sepsis HIftSo. Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated with Organ Dysfunction (ESCAPE) 2020 (Available from: ClinicalTrials.gov Identifier: NCT04339712.
[78] Paris AP-Hd. CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection (CORIMUNO-ANA) 2020 (Available from: ClinicalTrials.gov Identifier: NCT04341584.
[79] Early Treatment of Cytokine Storm Syndrome in Covid-19 (Internet). ClinicalTrials.gov Identifier: NCT04362111. 2020.
[80] Bart N. Lambrecht UH, Ghent. Treatment of COVID-19 Patients With Anti-interleukin Drugs (COV-AID). ClinicalTrials.gov Identifier: NCT043306382020
[81] Barber S. SCIL-1Ra in COVID-19 Feasibility & PK/PD (SCIL_COV19) ClinicalTrials.gov Identifier: NCT044627572020
[82] Servet FM. Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS) (ANA-COVID-GEAS) ClinicalTrials.gov Identifier: NCT044438812020
[83] Jonas Sundén-Cullberg KUH. A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study ClinicalTrials.gov Identifier: NCT044122912020
[84] Swedish Orphan Biovitrum WMCoCU. Anakinra, COVID-19, Cytokine Storm (SOBI) ClinicalTrials.gov Identifier: NCT046037422020
[85] Joseph GHPS. Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist (NET_COV) ClinicalTrials.gov Identifier: NCT045943562020
[86] Trust GsaSTNF. Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients with Acute Respiratory Distress Syndrome (ACES) ClinicalTrials.gov Identifier: NCT044083262020
[87] Anna Cruceta FCpalRB. Plasma Exchange in Patients with COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial (REP-COVID). ClinicalTrials.gov Identifier: NCT043745392020
[88] Center MSKC. A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy. ClinicalTrials.gov Identifier: NCT041484302020
[89] Martín JFB, Jiménez JL, MuEóz-Fernández A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Medical Science Monitor. 2003;9(6):SR29-SR34.
[90] Sebastian L, Desai A, Madhusudana SN, Ravi V. Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin. Int J Antimicrob Agents. 2009; 33(2):168-73.
[91] Sahebnasagh A, Mojtahedzadeh M, Najmeddin F, Najafi A, Safdari M, Ghaleno HR, et al. A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury/acute respiratory distress syndrome in patients with covid-19. Arch Med Res. 2020; 51(7): 631-635.
[92] Bermejo JF, Muñoz-Fernandez MA. Severe acute respiratory syndrome, a pathological immune response to the new coronavirus—implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology. Viral Immunol. 2004; 17(4):535-44.
[93] Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P. Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res. 2000; 91(1):70-6.
[94] Krysztopik RJ, Matheson PJ, Spain DA, Garrison RN, Wilson MA. Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res. 2000; 93(1):75-81.
[95] Staubach K-H, Schröder J, Stüber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg. 1998;133(1):94-100.
[96] Hamilçıkan Ş, Can E, Büke Ö, Erol M, Gayret ÖB. Pentoxifylline treatment of very low birth weight neonates with nosocomial sepsis. Am J Perinatol. 2017; 34(08):795-800.
[97] Montravers P, Fagon J-Y, Gilbert C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest. 1993;103(4):1017-22.
[98] Moriuchi H, Yuizono T. Pentoxifylline prevents a decrease in arterial oxygen tension in oleic acid-induced lung injury. Crit Care Med. 1995; 23(2):357-64.
[99] Myers MJ, Baarsch MJ, Murtaugh MP. Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine. Immunobiology. 2002; 205(1):17-34.
[100] Aikawa P, Zhang H, Barbas CS, Pazetti R, Correia C, Mauad T, et al. The effects of low and high tidal volume and pentoxifylline on intestinal blood flow and leukocyte-endothelial interactions in mechanically ventilated rats. Respir Care. 2011; 56[12):1942-9.
[101] Sawa T, Kinoshita M, Inoue K, Ohara J, Moriyama K. Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action. Antibodies. 2019;8(4):52.
[102] Alejandria MM, Lansang MAD, Dans LF, Mantaring III JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013(9).
[103] Nakamura K, Inokuchi R, Fukushima K, Naraba H, Takahashi Y, Sonoo T, et al. Single versus divided administration of intravenous immunoglobulin for sepsis: a retrospective and historical control study. Minerva Anestesiol. 2018; 85(2):156-63.
[104] Ishikura H, Nakamura Y, Kawano Y, Tanaka J, Mizunuma M, Ohta D, et al. Intravenous immunoglobulin improves sepsis-induced coagulopathy: A retrospective, single-center observational study. J Crit Care. 2015; 30(3):579-83.
[105] Morrison BJ, Roman JA, Luke TC, Nagabhushana N, Raviprakash K, Williams M, et al. Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A (H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy. J Virol Methods. 2017; 248:7-18.
[106] Gokturk B, Pekcan S, Guner SN, Artac H, Keles S, Kirac M, et al. Efficacy of intravenous immunoglobulin treatment in immunocompromised children with H1N1 influenza: a clinical observation. Clin Respir J. 2016; 10(2):223-30.
[107] Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018; 150:202-16.
[108] Tagami T, Matsui H, Fushimi K, Yasunaga H. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis. 2015;61(3):385-92.
[109] Wang C-H, Chan ED, Perng C-L, Chian C-F, Chen C-W, Perng W-C, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome. J Microbiol Immunol Infect. 2015; 48(2):229-32.
[110] Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006; 39(2):114-20.
[111] Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7(3):ofaa102.
[112] Ramos MFdP, Monteiro de Barros AdCM, Razvickas CV, Borges FT, Schor N. Xanthine oxidase inhibitors and sepsis. Int J Immunopathol Pharmacol. 2018; 32:2058738418772210.
[113] Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009; 179(10):903-13.
[114] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787.
[115] Montini F, Grenouillet F, Capellier G, Piton G. Strongyloidiasis: an unusual cause of septic shock with pneumonia and enteropathy in western countries. BMJ Case Rep. 2015; 2015:bcr2014209028.
[116] Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, selenoproteins and viral infection. Nutrients. 2019;11(9):2101.
[117] Rouini M, Rad NK, Najafi A, Sharifnia H, Dianatkhah M, Mojtahedzadeh M, et al. Oral Substitution of Melatonin in Critical Care: A Pharmacokinetic Study in Patients with Intracranial Hemorrhage. Journal of Pharmaceutical Care. 2020; 8(1): 3-10.
[118] Shahrami B, Sharif M, Forough AS, Najmeddin F, Arabzadeh AA, Mojtahedzadeh M. Antibiotic therapy in sepsis: No next time for a second chance! J Clin Pharm Ther. 2021; 46: 872–876.
[119] Chelkeba L, Ahmadi A, Abdollahi M, Najafi A, Ghadimi MH, Mosaed R, et al. The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial. Ann Intensive Care. 2015; 5(1):29.
[120] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-77.
[121] Mahmoodpoor A, Hamishehkar H, Shadvar K, Ostadi Z, Sanaie S, Saghaleini SH, et al. The effect of intravenous selenium on oxidative stress in critically ill patients with acute respiratory distress syndrome. Immunol Invest. 2019; 48(2):147-59.
[122] Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol. 2020:108409.
[2] Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020; 886:173451.
[3] Aguilar RB, Hardigan P, Mayi B, Sider D, Piotrkowski J, Mehta JP, et al. Current Understanding of COVID-19 Clinical Course and Investigational Treatments. Front Med (Lausanne). 2020; 7:555301.
[4] Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020; 2(10):e594-e602.
[5] Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-81.
[6] Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-47.
[7] Li Y, Wang S, Gao H, Wang J, Wei C, Chen L, et al. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence. Zhonghua Yi Xue Za Zhi. 2004; 84(16):1348.
[8] Azimi S, Sahebnasagh A, Sharifnia H, Najmeddin F. Corticosteroids Administration Following COVID-19-induced Acute Respiratory Distress Syndrome. Is it harmful or Life-saving? Front Emerg Med. 2020;4(2s):e43.
[9] Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005; 353(16):1711-23.
[10] Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-67.
[11] Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9.
[12] Yam LY-C, Lau AC-W, Lai FY-L, Shung E, Chan J, Wong V, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007; 54(1):28-39.
[13] Chen R-c, Tang X-p, Tan S-y, Liang B-l, Wan Z-y, Fang J-q, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6):1441-52.
[14] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473-5.
[15] Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet (London, England). 2020; 395(10225):683.
[16] Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020; 5(1):1-3.
[17] Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-43.
[18] Ni Y-N, Liu Y-M, Wang Y-W, Liang B-M, Liang Z-A. Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis. Am J Emerg Med. 2019; 37(9):1657-64.
[19] Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):e98-e106.
[20] Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care. 2019; 23(1):99.
[21] Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, et al. Adjunctive corticotherapy for community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2015; 10(12):e0144032.
[22] Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between Administration of Systemic Corticosteroids and Mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324(13):1330-41.
[23] Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021; 72(9):e373-e381.
[24] The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial. Chinese Clinical Trial Register (Internet) IC IC, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=50453
[25] Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure. Available from: ClinicalTrials.gov identifier (NCT number): NCT04244591 AFhcgcsNtNcC-dr.
[26] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000029656, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49086
[27] Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. MedRxiv. 2020.
[28] Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020; 52(1):1-5.
[29] Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014; 14(11):1090-5.
[30] Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020; 72(6):1446-1478.
[31] Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020; 25(4):668-88.
[32] Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl Jr J. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005; 326(4):905-8.
[33] Wang L-s, Wang Y-r, Ye D-w, Liu Q-q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020; 56(3): 106137.
[34] Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng C-TK, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol. 2008; 82(9):4471-9.
[35] Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N, et al. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc Natl Acad Sci U S A. 2006;103(34):12885-90.
[36] Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health. 2018; 11(1):9-17.
[37] Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI-P, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med. 2020; 9(3):623.
[38] Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
[39] Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88:106903.
[40] Jianping Z, Huilan Z. Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients. ClinicalTrials.gov identifier (NCT number): NCT04293887 AFhcgcsN.
[41] Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695-704.
[42] Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9).
[43] Li C, Luo F, Liu C, Xiong N, Xu Z, Zhang W, et al. Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients. Research Square. 2020.
[44] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000029989, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49720
[45] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000030013, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=49796
[46] Chinese Clinical Trial Register (Internet), Identifier: ChiCTR2000030480, Available from: http://www.chictr.org.cn/showprojen.aspx?proj=50470
[47] Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020; 85:106688.
[48] Payandemehr P, Azhdarzadeh M, Bahrami-Motlagh H, Hadadi A, Najmeddin F, Shahmirzaei S, et al. Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-Label Single-Arm Clinical Trial. Front Emerg Med. 2020;4(2s):e51.
[49] A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. ClinicalTrials.gov identifier (NCT number): NCT04254874.
[50] Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J-M, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 1996;24(3):392-7.
[51] Nakano K, Suzuki S. Stress-induced change in tissue levels of ascorbic acid and histamine in rats. J Nutr. 1984; 114(9):1602-8.
[52] Kuhn S-O, Meissner K, Mayes LM, Bartels K. Vitamin C in sepsis. Curr Opin Anaesthesiol. 2018; 31(1):55.
[53] Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020; 100190.
[54] Chang P, Liao Y, Guan J, Guo Y, Zhao M, Hu J, et al. Combined treatment with hydrocortisone, vitamin C, and thiamine for sepsis and septic shock (HYVCTTSSS): A randomized controlled clinical trial. Chest. 2020; 158(1):174-182.
[55] Iglesias J, Vassallo AV, Patel VV, Sullivan JB, Cavanaugh J, Elbaga Y. Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis. Chest. 2020; 158(1):164-173.
[56] Baladia E, Pizarro AB, Ortiz-Muñoz L, Rada G, Group C-LOW. Vitamin C for COVID-19: A living systematic review. Medwave. 2020; 20(6).
[57] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID‐19: A single center experience. J Med Virol. 2020; 92(7):814-8.
[58] Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020;18(1):1-5.
[59] Gheibi S, Najmeddin F, Shahrami B, Sadeghi K, Mojtahedzadeh M. The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19. J Pharm Care. 2020;8(3):140-2.
[60] Ibrahim YF, Moussa RA, Bayoumi AM, Ahmed A-SF. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein. Inflammopharmacology. 2020; 28(1):215-30.
[61] Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018; 23(8):943.
[62] Radigan KA, Nicholson TT, Welch LC, Chi M, Amarelle L, Angulo M, et al. Influenza A virus infection induces muscle wasting via IL-6 regulation of the E3 ubiquitin ligase atrogin-1. The Journal of Immunology. 2019; 202(2):484-93.
[63] Masui-Ito A, Okamoto R, Ikejiri K, Fujimoto M, Tanimura M, Nakamori S, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: Case report and review of literature. Medicine. 2017; 96(29).
[64] Roche H-L. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA). 2020; ClinicalTrials.gov Identifier: NCT04320615
[65] Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020; 20(5):269-70.
[66] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-5.
[67] Tongji Hospital HXH, Hospital WN, hospital Wc. Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS) clinicaltrials.gov Identifier: NCT043067052020
[68] Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis (Internet). 2020; ClinicalTrials.gov Identifier: NCT04315480.
[69] Giamarellos-Bourboulis EJ. Supar-Guided Anakinra Treatment For Validation Of The Risk And Early Management Of Severe Respiratory Failure By Covid-19. 2020; ClinicalTrials.gov Identifier: NCT04357366
[70] Giamarellos-Bourboulis EJ, Netea MG. A Personalized Randomized Trial Of Validation And Restoration Of Immune Dysfunction In Severe Infections And Sepsis (The Provide Trial). 2017; ClinicalTrials.gov Identifier: NCT03332225
[71] Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014; 15(5):401-8.
[72] Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: Re-analysis of a prior Phase III trial. Crit Care Med. 2016; 44(2):275-81.
[73] Nowill AE, de Campos-Lima PO. Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2–Induced Cytokine Storm. J Immunol. 2020; 205(10):2566-2575.
[74] Mer CHIdTLSs. Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV) (JAKINKOV) ClinicalTrials.gov Identifier: NCT043662322020
[75] Pedro Abizanda CHUdA. Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults (COVID-AGE). 2020; Available from: NCT04362943.
[76] Biovitrum SO. Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients with COVID-19 Infection. 2020; Available from: NCT04324021
[77] Sepsis HIftSo. Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated with Organ Dysfunction (ESCAPE) 2020 (Available from: ClinicalTrials.gov Identifier: NCT04339712.
[78] Paris AP-Hd. CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection (CORIMUNO-ANA) 2020 (Available from: ClinicalTrials.gov Identifier: NCT04341584.
[79] Early Treatment of Cytokine Storm Syndrome in Covid-19 (Internet). ClinicalTrials.gov Identifier: NCT04362111. 2020.
[80] Bart N. Lambrecht UH, Ghent. Treatment of COVID-19 Patients With Anti-interleukin Drugs (COV-AID). ClinicalTrials.gov Identifier: NCT043306382020
[81] Barber S. SCIL-1Ra in COVID-19 Feasibility & PK/PD (SCIL_COV19) ClinicalTrials.gov Identifier: NCT044627572020
[82] Servet FM. Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS) (ANA-COVID-GEAS) ClinicalTrials.gov Identifier: NCT044438812020
[83] Jonas Sundén-Cullberg KUH. A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study ClinicalTrials.gov Identifier: NCT044122912020
[84] Swedish Orphan Biovitrum WMCoCU. Anakinra, COVID-19, Cytokine Storm (SOBI) ClinicalTrials.gov Identifier: NCT046037422020
[85] Joseph GHPS. Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist (NET_COV) ClinicalTrials.gov Identifier: NCT045943562020
[86] Trust GsaSTNF. Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients with Acute Respiratory Distress Syndrome (ACES) ClinicalTrials.gov Identifier: NCT044083262020
[87] Anna Cruceta FCpalRB. Plasma Exchange in Patients with COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial (REP-COVID). ClinicalTrials.gov Identifier: NCT043745392020
[88] Center MSKC. A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy. ClinicalTrials.gov Identifier: NCT041484302020
[89] Martín JFB, Jiménez JL, MuEóz-Fernández A. Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Medical Science Monitor. 2003;9(6):SR29-SR34.
[90] Sebastian L, Desai A, Madhusudana SN, Ravi V. Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin. Int J Antimicrob Agents. 2009; 33(2):168-73.
[91] Sahebnasagh A, Mojtahedzadeh M, Najmeddin F, Najafi A, Safdari M, Ghaleno HR, et al. A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury/acute respiratory distress syndrome in patients with covid-19. Arch Med Res. 2020; 51(7): 631-635.
[92] Bermejo JF, Muñoz-Fernandez MA. Severe acute respiratory syndrome, a pathological immune response to the new coronavirus—implications for understanding of pathogenesis, therapy, design of vaccines, and epidemiology. Viral Immunol. 2004; 17(4):535-44.
[93] Koo DJ, Yoo P, Cioffi WG, Bland KI, Chaudry IH, Wang P. Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res. 2000; 91(1):70-6.
[94] Krysztopik RJ, Matheson PJ, Spain DA, Garrison RN, Wilson MA. Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism. J Surg Res. 2000; 93(1):75-81.
[95] Staubach K-H, Schröder J, Stüber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg. 1998;133(1):94-100.
[96] Hamilçıkan Ş, Can E, Büke Ö, Erol M, Gayret ÖB. Pentoxifylline treatment of very low birth weight neonates with nosocomial sepsis. Am J Perinatol. 2017; 34(08):795-800.
[97] Montravers P, Fagon J-Y, Gilbert C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest. 1993;103(4):1017-22.
[98] Moriuchi H, Yuizono T. Pentoxifylline prevents a decrease in arterial oxygen tension in oleic acid-induced lung injury. Crit Care Med. 1995; 23(2):357-64.
[99] Myers MJ, Baarsch MJ, Murtaugh MP. Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine. Immunobiology. 2002; 205(1):17-34.
[100] Aikawa P, Zhang H, Barbas CS, Pazetti R, Correia C, Mauad T, et al. The effects of low and high tidal volume and pentoxifylline on intestinal blood flow and leukocyte-endothelial interactions in mechanically ventilated rats. Respir Care. 2011; 56[12):1942-9.
[101] Sawa T, Kinoshita M, Inoue K, Ohara J, Moriyama K. Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action. Antibodies. 2019;8(4):52.
[102] Alejandria MM, Lansang MAD, Dans LF, Mantaring III JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013(9).
[103] Nakamura K, Inokuchi R, Fukushima K, Naraba H, Takahashi Y, Sonoo T, et al. Single versus divided administration of intravenous immunoglobulin for sepsis: a retrospective and historical control study. Minerva Anestesiol. 2018; 85(2):156-63.
[104] Ishikura H, Nakamura Y, Kawano Y, Tanaka J, Mizunuma M, Ohta D, et al. Intravenous immunoglobulin improves sepsis-induced coagulopathy: A retrospective, single-center observational study. J Crit Care. 2015; 30(3):579-83.
[105] Morrison BJ, Roman JA, Luke TC, Nagabhushana N, Raviprakash K, Williams M, et al. Antibody-dependent NK cell degranulation as a marker for assessing antibody-dependent cytotoxicity against pandemic 2009 influenza A (H1N1) infection in human plasma and influenza-vaccinated transchromosomic bovine intravenous immunoglobulin therapy. J Virol Methods. 2017; 248:7-18.
[106] Gokturk B, Pekcan S, Guner SN, Artac H, Keles S, Kirac M, et al. Efficacy of intravenous immunoglobulin treatment in immunocompromised children with H1N1 influenza: a clinical observation. Clin Respir J. 2016; 10(2):223-30.
[107] Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res. 2018; 150:202-16.
[108] Tagami T, Matsui H, Fushimi K, Yasunaga H. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. Clin Infect Dis. 2015;61(3):385-92.
[109] Wang C-H, Chan ED, Perng C-L, Chian C-F, Chen C-W, Perng W-C, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome. J Microbiol Immunol Infect. 2015; 48(2):229-32.
[110] Pourpak Z, Aghamohammadi A, Sedighipour L, Farhoudi A, Movahedi M, Gharagozlou M, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect. 2006; 39(2):114-20.
[111] Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020; 7(3):ofaa102.
[112] Ramos MFdP, Monteiro de Barros AdCM, Razvickas CV, Borges FT, Schor N. Xanthine oxidase inhibitors and sepsis. Int J Immunopathol Pharmacol. 2018; 32:2058738418772210.
[113] Gasse P, Riteau N, Charron S, Girre S, Fick L, Pétrilli V, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009; 179(10):903-13.
[114] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787.
[115] Montini F, Grenouillet F, Capellier G, Piton G. Strongyloidiasis: an unusual cause of septic shock with pneumonia and enteropathy in western countries. BMJ Case Rep. 2015; 2015:bcr2014209028.
[116] Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, selenoproteins and viral infection. Nutrients. 2019;11(9):2101.
[117] Rouini M, Rad NK, Najafi A, Sharifnia H, Dianatkhah M, Mojtahedzadeh M, et al. Oral Substitution of Melatonin in Critical Care: A Pharmacokinetic Study in Patients with Intracranial Hemorrhage. Journal of Pharmaceutical Care. 2020; 8(1): 3-10.
[118] Shahrami B, Sharif M, Forough AS, Najmeddin F, Arabzadeh AA, Mojtahedzadeh M. Antibiotic therapy in sepsis: No next time for a second chance! J Clin Pharm Ther. 2021; 46: 872–876.
[119] Chelkeba L, Ahmadi A, Abdollahi M, Najafi A, Ghadimi MH, Mosaed R, et al. The effect of parenteral selenium on outcomes of mechanically ventilated patients following sepsis: a prospective randomized clinical trial. Ann Intensive Care. 2015; 5(1):29.
[120] Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-77.
[121] Mahmoodpoor A, Hamishehkar H, Shadvar K, Ostadi Z, Sanaie S, Saghaleini SH, et al. The effect of intravenous selenium on oxidative stress in critically ill patients with acute respiratory distress syndrome. Immunol Invest. 2019; 48(2):147-59.
[122] Gasmi A, Noor S, Tippairote T, Dadar M, Menzel A, Bjørklund G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol. 2020:108409.
| Files | ||
| Issue | Vol 7 No 4 (2021): Autumn |
|
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/aacc.v7i4.7633 | |
| Keywords | ||
| Sars-CoV-2 Drugs adjuvant therapies | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Sadremomtaz A, Hashemi J, Sahebnasagh A, Nabavi SM, M.Al-Dahmani Z, Gheibi S, Shahrami B, Mosaed R, Arfa P, Roshanzamiri S, Mojtahedzadeh M. A Possible Guide as a Tool to Complementary Effects of New Coronavirus. Arch Anesth & Crit Care. 2021;7(4):253-277.
